SCHEMBL101672

SCHEMBL101672

CC1(c2ccc3c(c2)OCC3)NC(=O)NC1=O

nearest known ligand 0.47

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.47
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
AKR1B10 O60218 1/20 0.39
MAPT P10636 1/20 0.39
AKR1A1 P14550 1/20 0.39
AKR1B1 P15121 1/20 0.39
ADAM17 P78536 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL104120 0.89 LMNA (0.47) LMNAMEN1KMT2AAKR1B10MAPT
SCHEMBL103407 0.84 LMNA (0.50) LMNAMEN1KMT2AAKR1B10MAPT
SCHEMBL4317934 0.82 LMNA (0.46) LMNAMEN1KMT2AAKR1B10MAPT
SCHEMBL543048 0.82 LMNA (0.48) LMNAMEN1KMT2AAKR1B10MAPT
SCHEMBL102280 0.78 LMNA (0.50) LMNAMEN1KMT2AMAPTAKR1B1
SCHEMBL542454 0.78 LMNA (0.52) LMNAMEN1KMT2AMAPTAKR1B1
SCHEMBL1091785 0.78 LMNA (0.47) LMNAMEN1KMT2AMAPTADAM17
SCHEMBL1091957 0.76 LMNA (0.45) LMNAMEN1KMT2AAKR1B1ADAM17
SCHEMBL1100833 0.74 AKR1B1 (0.42) LMNAMEN1KMT2AAKR1B1ADAM17
SCHEMBL103988 0.72 LMNA (0.47) LMNAMEN1KMT2AAKR1B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2426113-B1 CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER KOWA CO (JP) 2013-11-06 EP disclosed
US-8551985-B2 Carbinol derivatives having heterocyclic linker KOWA COMPANY, LTD. (JP) 2013-10-08 US disclosed
US-8153634-B2 Carbinol derivatives having cyclic linker KOWA COMPANY, LTD. (JP) 2012-04-10 US disclosed
EP-2426113-A1 CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER Kowa Company, Ltd. (JP) 2012-03-07 EP disclosed
EP-2281817-A1 SUBSTITUTED CARBINOL COMPOUND HAVING CYCLIC LINKER Kowa Company, Ltd. (JP) 2011-02-09 EP disclosed
US-20100280013-A1 CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER KOWA COMPANY, LTD. (JP) 2010-11-04 US disclosed
US-20100048610-A1 CARBINOL DERIVATIVES HAVING CYCLIC LINKER KOWA COMPANY, LTD. (JP) 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280013-A1 CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER NR1H2, NR1H3, CCR2 LMNA 1575/4885MEN1 3479/4885KMT2A 2327/4885
US-20100048610-A1 CARBINOL DERIVATIVES HAVING CYCLIC LINKER NR1H2, NR1H3, LDLR LMNA 1288/4885MEN1 3823/4885KMT2A 2383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.